Clinical Trials Register

Trials with a EudraCT protocol (599)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

599 result(s) found for: Lung cancer screening. Displaying page 1 of 30.

EudraCT Number: 2009-012607-26

Sponsor Protocol Number: MIMEB

Start Date*: 2009-12-10

Sponsor Name:University of Cologne

Full Title: MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Adv...

Medical condition: Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC), first-line.

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.0		10025054	Lung cancer non-small cell stage IIIB	LLT
	12.0		10025055	Lung cancer non-small cell stage IV	LLT
	12.0		10029515	Non-small cell lung cancer recurrent	PT
	12.0		10029521	Non-small cell lung cancer stage IIIB	PT
	12.0		10029522	Non-small cell lung cancer stage IV	PT
	12.0		10029521	Non-small cell lung cancer stage IIIB	LLT
	12.0		10029522	Non-small cell lung cancer stage IV	LLT
	12.0		10050017	Lung cancer metastatic	LLT
	12.0		10059515	Non-small cell lung cancer metastatic	LLT
	12.0		10061873	Non-small cell lung cancer	LLT
	12.0		10066490	Progression of non-small cell lung cancer	LLT
	12.0		10050017	Lung cancer metastatic	PT
	12.0		10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

EudraCT Number: 2007-005245-37

Sponsor Protocol Number: M06-880

Start Date*: 2008-04-17

Sponsor Name:Abbott GmbH & Co. KG

Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10061873	Non-small cell lung cancer	LLT
	9.1		10059515	Non-small cell lung cancer metastatic	LLT
	9.1		10029514	Non-small cell lung cancer NOS	LLT
	9.1		10029515	Non-small cell lung cancer recurrent	LLT
	9.1		10029516	Non-small cell lung cancer stage 0	LLT
	9.1		10029517	Non-small cell lung cancer stage I	LLT
	9.1		10029518	Non-small cell lung cancer stage II	LLT
	9.1		10029519	Non-small cell lung cancer stage III	LLT
	9.1		10029520	Non-small cell lung cancer stage IIIA	LLT
	9.1		10029521	Non-small cell lung cancer stage IIIB	LLT
	9.1		10029522	Non-small cell lung cancer stage IV	LLT
	9.1		10059515	Non-small cell lung cancer metastatic	LLT
	9.1		10029515	Non-small cell lung cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2021-005729-25

Sponsor Protocol Number: LUNGVAC

Start Date*: 2022-05-09

Sponsor Name:Vestre Viken Health Trust

Full Title: A Randomized Phase II, Open-label, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1 treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced ...

Medical condition: Inoperable advanced or metastatic non-small cell lung cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050017	Lung cancer metastatic	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025044	Lung cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NO (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-001005-85

Sponsor Protocol Number: ATX-NS-001

Start Date*: 2021-07-06

Sponsor Name:Achilles Therapeutics UK Limited

Full Title: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer.

Medical condition: Non-small cell lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001245	Adenosquamous cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001247	Adenosquamous cell lung cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001251	Adenosquamous cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001254	Adenosquamous cell lung cancer stage IV	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023775	Large cell lung cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023779	Large cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023780	Large cell lung cancer stage IV	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10050017	Lung cancer metastatic	PT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025044	Lung cancer	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001246	Adenosquamous cell lung cancer NOS	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029514	Non-small cell lung cancer NOS	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001253	Adenosquamous cell lung cancer stage IIIB	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10023774	Large cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001252	Adenosquamous cell lung cancer stage IIIA	LLT
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025048	Lung cancer non-small cell recurrent	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025052	Lung cancer non-small cell stage III	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025054	Lung cancer non-small cell stage IIIB	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025053	Lung cancer non-small cell stage IIIA	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025055	Lung cancer non-small cell stage IV	LLT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066490	Progression of non-small cell lung cancer	LLT
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10069730	Large cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) NL (Completed)

Trial results: (No results available)

EudraCT Number: 2020-002773-10

Sponsor Protocol Number: IRFMN-LUNG-8287

Start Date*: 2022-03-14

Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Full Title: A phase III prevention trial of canakinumab in subjects at high risk for lung cancer

Medical condition: Subjects at high risk for lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10058467	Lung neoplasm malignant	PT
	20.0	100000004865	10078411	Primary prevention	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2007-007107-32

Sponsor Protocol Number: M10-301

Start Date*: 2009-07-31

Sponsor Name:Abbott GmbH & Co. KG

Full Title: A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study of Carboplatin /Paclitaxel in Combination with ABT-869 Versus Carboplatin/Paclitaxel Alone in Subjects with Advanced or Metastatic Non-S...

Medical condition: Non small cell lung cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10029514	Non-small cell lung cancer NOS	LLT
	9.1		10029515	Non-small cell lung cancer recurrent	LLT
	9.1		10059515	Non-small cell lung cancer metastatic	LLT
	9.1		10029516	Non-small cell lung cancer stage 0	LLT
	9.1		10029517	Non-small cell lung cancer stage I	LLT
	9.1		10029518	Non-small cell lung cancer stage II	LLT
	9.1		10029519	Non-small cell lung cancer stage III	LLT
	9.1		10029520	Non-small cell lung cancer stage IIIA	LLT
	9.1		10029521	Non-small cell lung cancer stage IIIB	LLT
	9.1		10029522	Non-small cell lung cancer stage IV	PT
	9.1		10059515	Non-small cell lung cancer metastatic	PT
	9.1		10029515	Non-small cell lung cancer recurrent	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed)

Trial results: View results

EudraCT Number: 2010-018614-70

Sponsor Protocol Number: D791AC00014

Start Date*: 2010-09-03

Sponsor Name:AstraZeneca AB

Full Title: An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First line Treatment in Caucasian Patients, who have Epidermal Gr...

Medical condition: Non Small Cell Lung Cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10025053	Lung cancer non-small cell stage IIIA	LLT
	12.1		10025054	Lung cancer non-small cell stage IIIB	LLT
	12.1		10025055	Lung cancer non-small cell stage IV	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PT (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed) NO (Completed) HU (Completed) GR (Completed) BG (Completed)

Trial results: View results

EudraCT Number: 2015-003715-38

Sponsor Protocol Number: D4190C00006

Start Date*: 2016-05-12

Sponsor Name:MedImmune LLC

Full Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer

Medical condition: Locally advanced or metastatic squamous or nonsquamous non- small cell lung cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10066490	Progression of non-small cell lung cancer	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed)

Trial results: View results

EudraCT Number: 2019-002192-33

Sponsor Protocol Number: TRADEhypo

Start Date*: 2020-02-06

Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Full Title: Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy- Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy

Medical condition: unresectable stage III NSCLC (Non–small-cell lung cancer)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029520	Non-small cell lung cancer stage IIIA	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025052	Lung cancer non-small cell stage III	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025054	Lung cancer non-small cell stage IIIB	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025053	Lung cancer non-small cell stage IIIA	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2014-001436-10

Sponsor Protocol Number: INCB18424-266

Start Date*: 2015-02-26

Sponsor Name:Incyte Corporation

Full Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non–Small C...

Medical condition: Nonsquamous NSCLC that is Stage IIIB, Stage IV, or recurrent

Disease:	Version	SOC Term	Classification Code	Term	Level
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) PT (Completed)

Trial results: View results

EudraCT Number: 2014-002161-30

Sponsor Protocol Number: 1302.5

Start Date*: 2015-09-07

Sponsor Name:Boehringer Ingelheim International GmbH

Full Title: A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Sm...

Medical condition: Recurrent or metastatic disease (Stage IV), histologically or cytologically confirmed advanced nonsquamous Non-Small Cell Lung Cancer.

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029515	Non-small cell lung cancer recurrent	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: HU (Completed) PT (Completed) ES (Completed) DE (Completed) PL (Completed) HR (Completed) GR (Completed)

Trial results: View results

EudraCT Number: 2020-003512-27

Sponsor Protocol Number: AIO-YMO/TRK-0120

Start Date*: 2021-12-08

Sponsor Name:AIO-Studien-gGmbH

Full Title: Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study

Medical condition: Patients with EGFR-mutation positive NSCLC The target population will comprise 3 parallel cohorts, for each of which a minimum of 10 subjects is planned to be enrolled: 1. Irradiation of bone, sol...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10025064	Lung carcinoma	LLT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10007096	Cancer of lung	LLT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2016-002579-83

Sponsor Protocol Number: 54767414LUC2001

Start Date*: 2017-02-24

Sponsor Name:Janssen-Cilag International NV

Full Title: A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic N...

Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	19.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) HU (Completed) FR (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2010-023854-35

Sponsor Protocol Number: CD-ON-MEDI-575-1031

Start Date*: 2011-11-07

Sponsor Name:MedImmune, LLC

Full Title: A Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Subjects With Previously Untreated, Advanced Non-Small Ce...

Medical condition: Previously untreated advanced non-small cell lung cancer in adults

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) HU (Completed) BG (Prematurely Ended)

Trial results: View results

EudraCT Number: 2012-005541-21

Sponsor Protocol Number: CBKM120D2204

Start Date*: 2013-06-20

Sponsor Name:NOVARTIS FARMA

Full Title: A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-s...

Medical condition: squamous non small cell lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001254	Adenosquamous cell lung cancer stage IV	PT
	14.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10001253	Adenosquamous cell lung cancer stage IIIB	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IT (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) CZ (Completed) BE (Completed) HU (Completed)

Trial results: View results

EudraCT Number: 2020-002829-28

Sponsor Protocol Number: B8011011

Start Date*: 2021-06-01

Sponsor Name:Pfizer Inc.

Full Title: A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined with Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Medical condition: locally advanced or metastatic NSCLC

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed) NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2017-002359-27

Sponsor Protocol Number: D5161C00003

Start Date*: 2017-11-13

Sponsor Name:AstraZeneca AB

Full Title: A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients with EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated with Osimertinib

Medical condition: EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer not amenable to curative surgery or radiotherapy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029521	Non-small cell lung cancer stage IIIB	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10059515	Non-small cell lung cancer metastatic	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) IT (Completed)

Trial results: View results

EudraCT Number: 2017-003560-13

Sponsor Protocol Number: OTL-2016-OTL38-005

Start Date*: 2017-10-18

Sponsor Name:On Target Laboratories, LLC

Full Title: A Phase 2, Single dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Medical condition: adenocarcinoma lung cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10025044	Lung cancer	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: (No results available)

EudraCT Number: 2021-005136-34

Sponsor Protocol Number: THIO101

Start Date*: 2022-11-16

Sponsor Name:MAIA Biotechnology, Inc.

Full Title: A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)

Medical condition: Non-Small Cell Lung Cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10061873	Non-small cell lung cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029519	Non-small cell lung cancer stage III	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029522	Non-small cell lung cancer stage IV	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Trial now transitioned) PL (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2015-000307-10	Sponsor Protocol Number: TREM	Start Date*: 2015-05-27
Sponsor Name:Oslo university hospital
Full Title: AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.
Medical condition: Locally advanced or metastatic non-small cell lung cancer where disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NO (Completed) DK (Completed) FI (Completed) LT (Completed) SE (Ongoing)
Trial results: (No results available)

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Lung cancer screening